Business
Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health
Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18th announcement regarding the formation "Izotropic Africa" under a Letter Agreement, the...
About this update from Izotropic Corp.
[{"type":"text","content":"Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18th announcement regarding the formation "Izotropic Africa" under a Letter Agreement, the proposed Casablanca-based entity has entered into partnership discussions with the Mohammed VI Foundation for Science & Health ("FM6SS"). The FM6SS operates as a public utility institution under the patronage of King Mohammed VI, supporting healthcare reform, research advancement, innovation, and institutional partnerships within Morocco.","length":882,"tagName":"p"},{"type":"text","content":"Izotropic Africa is being developed to pursue the licensing, marketing, and distribution of the Company's proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Under the Letter Agreement, Izotropic will hold a 40% fully diluted interest in Izotropic Africa, subject to conditions, and the parties have agreed to negotiate in good faith to finalize and enter into a Formal Agreement by April 30, 2026.","length":567,"tagName":"p"},{"type":"text","content":"The partnership discussions between Izotropic Africa and the FM6SS are focused on clinical research, regulatory advancement, and manufacturing and assembly opportunities in Morocco for the Company's proprietary medical device, the IzoView Breast CT Imaging System. As part of these discussions, an IzoView device valued at USD $500K would be placed at a leading hospital in Morocco at no cost as a clinical research site to support local clinical evaluation and regulatory approvals. The discussions also include the evaluation of opportunities for localized manufacturing and assembly initiatives in Morocco, with the kingdom's geographic position at the intersection of Europe, Africa, and the Middle East providing access to regional markets with established logistics channels.","length":789,"tagN...